Europe
MC2 Therapeutics announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for Wynzora™ Cream.
Series A round lead investors NordicNinja and Industrifonden to support Combinostics as they scale to US and Asia
Vivoryon Therapeutics AG, will publish its third quarter financial results and a business update for the period ended September 30, 2019 on Thursday, November 28, 2019, in the form of an interim management report.
MorphoSys AG announced that Dr. Markus Enzelberger, the company’s Chief Scientific Officer, has decided to step down as CSO and member of the company’s Management Board to explore new opportunities. Dr. Enzelberger will leave MorphoSys on February 29, 2020.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s appointments.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The company’s consumer health unit is worth about $30 billion.
A new Atrial Fibrillation Management Report highlights that catheter ablation is almost 10 times more effective at delaying Atrial Fibrillation progression than drug therapy, yet just 4% of eligible patients are receiving ablation therapy
Meet Teckro: the machine-learning platform revolutionizing the way clinical trials are run
Heidelberg Pharma contributing Antibody Targeted Amanitin Conjugate technology for Emergence Therapeutics antibody target
PRESS RELEASES